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ABSTRACT
T
he recent revelation that there are small, noncoding
RNAs that regulate the expression of many other
genes has led to an exciting, emerging body of
literature deﬁning the biological role for these molecules
within signaling networks. In a ﬂurry of recent papers, a
microRNA polycistron induced by the oncogenic
transcription factor c-myc has been found to be involved in an
unusually structured network of interactions. This network
includes the seemingly paradoxical transcriptional induction
and translational inhibition of the same molecule, the E2F1
transcription factor. This microRNA cluster has been
implicated in inhibiting proliferation, as well as inhibiting
apoptosis, and promoting angiogenesis. Consistent with its
seemingly paradoxical functions, the region of the genome in
which it is encoded is deleted in some tumors and
overexpressed in others. We consider the possibility that
members of this polycistronic microRNA cluster help cells to
integrate signals from the environment and decide whether a
signal should be interpreted as proliferative or apoptotic.
Introduction
microRNAs are 21–23-nucleotide noncoding RNAs
processed from double-stranded hairpin precursors present
in a wide range of organisms including worms, plants, ﬂies,
and mammals [1,2]. microRNAs are loaded into the RNA-
induced silencing complex and subsequently hybridize to
complementary sequences in target mRNAs. This results in
inhibition of mRNA translation or reduced message stability
[3,4]. Microarray analyses suggest that individual microRNAs
can regulate hundreds of genes [5]. This ﬁnding has raised the
interesting possibility that microRNAs can coordinate
complex cellular responses. One emerging model of the role
of microRNAs is to maintain the robustness of genetic
networks by ensuring that genes that ought to be ‘‘off’’ are
downregulated not only via decreased transcription but also
by translational inhibition (Text Box 1) [6,7]. Recently,
however, a microRNA cluster was found to be involved in a
complex network structured like a feed forward loop
(described further in Text Box 2). This network appears to
play a central role in controlling proliferation, apoptosis and
tumorigenesis.
The miR-17–92 Cluster
Many microRNAs are present within the genome not as an
individual microRNA but rather as clusters of multiple
microRNAs [8,9]. Usually these clusters contain two or three
genes but larger clusters exist, including the miR-17–92
cluster, which contains seven mature microRNAs (miR-17–5p,
miR-17–3p, miR-18a, miR-19a, miR-20a, miR-19b, and miR-92–
1). These microRNAs are organized in a polycistron; that is,
they are all transcribed as a single pri-microRNA, and then
subsequently processed to form the individual microRNAs.
The entire miR-17–92 cluster is located within the third
intron of an open reading frame termed the C13orf25
(Chromosome 13 open reading frame 25) gene located at
13q31–q32. The close proximity of the six clustered
microRNAs to each other (all six encompass only ;800 base
pairs of genomic DNA) makes it possible for all of the
microRNAs to be transcribed and expressed similarly. In fact,
a recent analysis of the expression of microRNAs in
hematopoietic cell lines revealed similar expression patterns
for all of the microRNAs in this cluster in the samples
analyzed [8].
Myc and E2F Induce Expression of miR-17–92, and
Individual microRNAs Inhibit E2F Translation
O’Donnell and colleagues demonstrated that activation of
the oncogenic transcription factor c-myc induces the
expression of microRNAs within the miR-17–92 cluster [10].
Chromatin immunoprecipitation conﬁrmed that c-myc binds
to its recognition sites, E-boxes, upstream of this cluster.
Serum stimulation of ﬁbroblasts induced the expression of c-
myc and the miR-17–92 cluster with similar kinetics. Two of
the microRNAs within the cluster, mir17-5p and miR-20a,
downregulated the protein—but not mRNA—abundance of
their predicted target, the transcription factor E2F1.
Transfection of antisense oligonucleotides that inhibit miR-
17–5p or miR-20a resulted in increased E2F1 protein levels
without affecting E2F1 transcript abundance. Consistent with
this ﬁnding, c-myc induction led to a strong increase in E2F1
transcript levels, but only a modest increase in E2F1 protein
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each other’s transcription [11–13], this established an
unusually structured network in which c-myc activates the
transcription of E2F1 while simultaneously inhibiting its
translation (Figure 1). The importance of the miR-17–5p/miR-
20a binding sites for E2F1 expression were demonstrated with
reporter assays [10,14]. The 39 UTRs of E2F2 and E2F3 were
also regulated via miR-17–5p/miR-20a binding sites, but the
downregulation of E2F1 protein levels was stronger than for
E2F2 or E2F3 [14].
To make matters even more complicated, the E2F
transcription factors can also induce the microRNAs in the
miR-17–92 cluster [14,15]. Overexpression of E2F1 or E2F3
results in increased miR-17–92 promoter activity [14,15].
Chromatin immunoprecipitation experiments by Woods and
colleagues revealed stronger binding for E2F3 than E2F1 or
E2F2 in three different regions of the miR-17–92 cluster,
conﬁrming a likely role for E2F3 in miR-17–92 expression.
Because a control promoter at which all E2Fs are known to
bind also resulted in stronger bands for E2F3 than for E2F1
or E2F2, this may reﬂect greater binding efﬁciency of the
E2F3 antibody. Sylvestre and colleagues similarly concluded
that immunoprecipitation followed by PCR resulted in bands
of similar intensity for E2F1, E2F2, and E2F3 in one DNA
region and a stronger band for E2F3 in a different region,
which may also reﬂect higher binding afﬁnity of E2F3 for this
region, or higher binding afﬁnity of the E2F3 antibody [14].
These ﬁndings suggest a complex network structure
summarized in Figure 1.
Can miR-17–92 Prevent Runaway myc-E2F
Activation?
Because c-myc and E2F1, E2F2, and E2F3 can activate one
another’s transcription [11–13], one might imagine a cell in a
runaway positive feedback loop in which c-myc induces the
E2F transcription factors, which induce each other and, in
turn, c-myc. This would result in excessively high levels of
proliferative transcriptional regulators. High levels of c-myc
have been clearly shown to have a tumor-promoting effect
[16]. Just 2-fold differences in c-myc expression can affect cell
size in ﬂies or cell number in mice [17–20]. Indeed,
dysregulated expression of c-myc is one of the most common
abnormalities in human malignancy [21]. Thus, maintaining c-
myc levels within a tight range can be considered critical for
the prevention of cancer and accordingly, c-myc levels are
tightly controlled at the level of transcription [16,22]. One
hypothesized role for the miR-17–92 cluster is to further the
goal of carefully minimizing noise in c-myc levels. By ensuring
that E2F1 protein levels do not rise precipitously in response
doi:10.1371/journal.pgen.0030146.g001
Figure 1. The Interactions among c-myc, the E2F1, E2F2, and E2F3
Transcription Factors and the microRNAs of the miR-17–92 Complex Are
Shown
Black arrows indicate a transcriptional induction. Bidirectional arrows
indicate mutual transcriptional induction. Darker arrows indicate
stronger evidence of regulation while dashed arrows indicate that the
evidence is less conclusive. Red lines indicate translational inhibition.
Darker lines indicate stronger inhibition and dashed lines indicate weaker
inhibition. Among members of the miR-17–92 cluster, only miR-17–5p
and miR-20a have been shown to inhibit E2F translation.
Box 1. Genetic Buffering
Molecular networks that can withstand chance perturbations and
reproducibly produce the same phenotypic results have been favored
over the course of evolution [7]. Genetic buffering refers to the
stabilization of molecular networks, making them less sensitive to
chance fluctuations in the levels of specific molecules. The best-
understood example of a specific molecule with the capacity to buffer
a network is the chaperone protein hsp90, which can serve as a capacitor
for the build-up of genetic variation. In Drosophila, when the heat-shock
protein hsp90 is mutated or impaired, phenotypes are observed in nearly
every adult structure [61]. Thus, widespread variation affecting
Drosophila morphogenetic pathways exists but is usually silent
because hsp90 buffers the variation. When hsp90 is incapacitated, for
instance, under conditions of high temperature, cryptic variants may be
revealed. This process may promote evolutionary change by increasing
phenotypic variance under stressful conditions. Chromatin regulators
have also been suggested to play a role as genetic buffers. A systematic
screen for interaction pairs in C. elegans revealed that six genes involved
in chromatin regulation interact with over one-quarter of all of the genes
tested [62]. As in the case of hsp90, inactivation of these ‘‘hub’’ genes
sensitized the animals to the phenotypic effects of knockdowns of many
different genes.
microRNAs have also been hypothesized to play a role in
‘‘canalization’’ or the increased robustness of phenotypic outcomes in
the presence of noise. In some well-studied examples, microRNAs have
been shown to reinforce the downregulation of transcripts in specific cell
types or at times when the encoded proteins should not be present [6,7].
In several recent papers, microRNAs have been elegantly associated with
regulatory loops that serve to reinforce lineage commitments, especially
the irreversible commitment to a specific cell fate [63–65]. Under these
conditions, a transient signal may result in one of two bistable states,
characterized by either low microRNA levels and high target levels, or
vice versa [64–66].
In addition to reinforcing low expression of genes that are intended to
be ‘‘off,’’ robustness can also be improved by minimizing ‘‘noise’’ in
protein expression levels similar to hsp90’s effects at the protein level.
The microRNAs of the miR-17–92 complex have been proposed to help
minimize noise in the levels of the E2F1 protein [7,23]. Because
transcription is an inherently noisy process, frequent transcription
coupled with infrequent translation results in lower intrinsic noise in
protein levels compared with infrequent transcription [67–70].
Accordingly, in yeast, genes that are key regulators or essential have
high rates of transcription and low rates of translation [71]. In this model,
the miR-17–92 cluster could limit the extent of translation, thus allowing
the cell to make many mRNA copies but have a low and carefully
controlled amount of protein. This model could be tested by
determining whether miR-17–92 actually affects inter-cell variability in
E2F protein levels [72]. The amount of noise could be monitored with
E2F1-YFP fusion proteins that include the relevant E2F 39 UTR in the
presence of scrambled 29-O-methyl oligoribonucleotides, or 29-O-methyl
oligoribonucleotides that target individual microRNAs within the cluster.
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possible positive feedback loop, thus helping to ensure tightly
controlled expression of c-myc and E2F1 proteins [10,23].
From this perspective, the miR-17–92 cluster might act as a
tumor suppressor. Consistent with this hypothesis, loss of
heterozygosity or deletion of the 13q31–32 region is observed
in multiple types of tumors, including squamous cell
carcinoma of the larynx [24], retinoblastoma [25],
hepatocellular carcinoma [26], breast cancer [27], and
nasopharyngeal carcinoma [28,29]. Copy number loss was
observed frequently for the microRNAs of the miR-17–92
cluster in breast cancers (21.9%), ovarian cancers (16.5%),
and melanomas (20.0%) [30]. In addition, miR-17–5p in
particular is expressed at low levels in multiple breast tumor
cell lines and has antiproliferative effects on breast cancer
cells [31].
Individual Members of the miR-17–92 Cluster Can
Also Inhibit Apoptosis
Paradoxically, while the miR-17–92 cluster has a putative
role as an inhibitor of proliferation described above, the
observed functional effect of overexpressing the microRNAs
within the miR-17–92 cluster is not to inhibit proliferation
but rather to induce proliferation and/or inhibit apoptosis.
As an example of the role of microRNAs in the miR-17–92
cluster in inhibiting apoptosis, introduction of miR-17–92 in
conjunction with c-myc overexpression resulted in B-cell
lymphomas characterized by an absence of the high levels of
apoptosis normally associated with c-myc-induced lymphomas
[32]. In in vitro studies, Sylvestre and colleagues
demonstrated that overexpression of miR-20a decreased
doxorubicin-induced cell death in a prostate cancer cell line,
while inhibition of miR-20a with antisense oligonucleotides
increased cell death after doxorubicin [14]. Matsubara and
colleagues discovered that antisense oligonucleotides
directed against miR-17–5p, miR-20a, or both result in
increased apoptosis as measured by TUNEL assays in cancer
cell lines overexpressing the miR-17–92 cluster [33]. Little
effect was observed when either miR-17–5p or miR-20a was
introduced into cell lines that do not overexpress miR-17–92,
or when antisense oligonucleotides against either miR-18a or
miR-19a were introduced. These ﬁndings demonstrate that
the microRNAs within this cluster have distinct functional
effects, with at least miR-17–5p and miR-20a speciﬁcally
inhibiting apoptosis.
Hayashita and colleagues also discovered that the
microRNAs of the miR-17–92 cluster promote proliferation.
Transfection of the entire miR-17–92 polycistron into lung
cancer cells resulted in increased rates of cellular
proliferation based on cell number. Introduction of the
coding region of the C13orf25 or the individual microRNAs
miR-18, miR-19a, or miR-20a did not recapitulate the growth-
promoting effects of the entire microRNA cluster [34]. Thus,
one or more of the microRNAs in the cluster (but not miR-18,
miR-19a, or miR-20a) may enhance proliferation via a
mechanism distinct from the anti-apoptotic effect of miR-17–
5p and miR-20a.
That the same microRNAs that inhibit E2F1 protein levels
(miR-17–5p and miR-20a) also inhibit apoptosis suggests that
E2F1 repression may be related to the inhibition of apoptosis
conferred by the miR-17–92 cluster. Indeed, the anti-
apoptotic activity of this cluster has been proposed to reﬂect
differences in the physiological effects of the different E2F
transcription factors. E2F1, as opposed to E2F2 or E2F3, has
been particularly associated with an apoptotic response. For
doi:10.1371/journal.pgen.0030146.g002
Figure 2. Two Molecules (X and Y) Can Both Regulate Molecule Z
Independently (A) or Can Form a Feed Forward Loop (B) in Which X
Regulates Z Both Directly and Indirectly via Y
Feed forward loops can be coherent as shown in (B), in which case the
direction of the regulation on Z is the same in either the direct or indirect
path, or incoherent, illustrated in (C), in which case the two pathways
have opposing effects on the target gene.
Box 2. Feed Forward Loops
Genetic networks contain repeated regulatory motifs including feed
forward loops. In biological systems, this motif has been defined as two
transcription factors, one of which regulates the other, and both of
which regulate a third gene (Figure 2). These transcription factor-based
loops can be ‘‘coherent,’’ in which case the sign of the direct path to the
target gene is the same as the sign of the indirect path to the reporter.
Alternatively, they can be ‘‘incoherent,’’ in which case the direct and
indirect paths have opposing effects on the target. For transcription
factor–based loops, both coherent and, less frequently, incoherent feed
forward loops have been identified in S. cerevisiae and E. coli [73]. In
human and mouse, incoherent loops involving microRNAs and their
targets have been inferred to be common based on microarray data [23].
Both coherent and incoherent feed forward loops involving two
transcription factors have been theoretically modeled and
experimentally tested [73,74]. The two components contributing to
expression of the reporter may be organized in an ‘‘AND’’ conformation,
such that both are required, or an ‘‘OR’’ conformation, so that either is
sufficient for expression. An incoherent feed forward loop can cause a
pulse of reporter activity under certain conditions. In this situation, the
upregulation kinetics are expected to be faster than if the two factors
were acting independently [73,75]. Indeed, in experimental systems, it
has been shown that an incoherent feed forward loop can lead to
accelerated turn-on dynamics, even if embedded within other loops
[74,75].
We speculate that the structure of the feed forward loop involved in
the c-myc–miR-17–92–E2F network may have an important impact on
the kinetics of E2F1 activation. The network structure embedded within
the c-myc–miR-17–92–E2F network may resemble a type I ‘‘incoherent’’
feed forward loop [73]. In the case of miR-17–92, microRNA-mediated
inhibition of translation could allow a pulse of E2F activity. Once
reaching a critical threshold, microRNAs could efficiently downregulate
translation of the existing transcripts, thereby preventing a further rise in
E2F1 abundance. This would allow a rapid shut-off of E2F1 activity that
would be independent of the kinetics of E2F1 transcript degradation.
Indeed, this mechanism might underlie the spike in E2F activity during
cell-cycle entry [76]. Whether this network does in fact result in a rapid
spike in E2F1 activity could be tested by a careful analysis of the time
course of miR-17–92 and E2F1 induction in response to c-myc activation.
A finding that E2F1 levels and activity are rapidly induced and then
decline following c-myc induction would support this model as a
possible advantage of the network structure discovered.
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signaling pathway [35]. And, E2F1-responsive sites are present
in the promoters of caspases and other pro-apoptotic
molecules [36,37]. Although E2F2 and E2F3 are also somewhat
downregulated by the microRNAs in the cluster based on
reporter assays [14], the effect on E2F1 is much stronger.
Thus, the miR-17–92 cluster has been proposed to inhibit
apoptosis by decreasing E2F1 levels [14,15].
Possible Role for Apoptosis Inhibition by miR-17–92
in Spermatocytes
A physiological role for apoptosis inhibition mediated by
miR-17–92 has been suggested in spermatocytes [38]. In
individual pachytene spermatocytes within a normal testis,
high levels of E2F1 message but low levels of protein were
associated on a cell-by-cell basis with high miR-17–92
expression. This has been suggested to reﬂect the particular
needs of spermatocytes, cells in which meiotic recombination
induces extensive crossing over of sister chromatids and
multiple double-strand breaks, which would be expected to
result in apoptosis [38]. Inhibition of E2F1 by miR-17–92
could be important for preventing apoptosis in these cells
during meiotic recombination. These ﬁndings suggest that
the miR-17–92 cluster may be important for inhibiting
apoptosis under conditions in which it would be detrimental
to the organism. In addition, this same mechanism for
apoptosis inhibition may be associated with tumorigenesis, as
described further below.
c-myc Induction of miR-17–92 Induces Tumor
Angiogenesis
c-myc has been reported to promote neovascularization via
upregulation of pro-angiogenic VEGF [39] and
downregulation of anti-angiogenic thrombospondin-1 (tsp-1)
[40,41]. In addition, Dews and colleagues recently discovered
that the miR-17–92 microRNA cluster also plays a role in c-
myc–induced angiogenesis in a ras–myc tumorigenesis model.
When engrafted into mice, cells overexpressing ras form small
tumors while overexpression of both c-myc and ras results in
larger tumors with much more robust neovascularization [42].
In cell culture, miR-17–92 levels were elevated in the presence
of overexpressed c-myc, and levels of predicted targets tsp-1
and connective tissue growth factor (CTGF) declined.
Transfection of antisense oligoribonucleotides revealed that
miR-18 is especially important for CTGF regulation and miR-
19 is important for tsp-1 regulation. Inhibition of miR-17,
miR-20a, or miR-92 had no effect on the levels of angiogenesis
target genes. Further, cells overexpressing both ras and miR-
17–92 had lower levels of CTGF and formed tumors that were
larger and more vascular than tumors formed by cells
expressing only ras.
miR-17–92 and c-myc Are Overexpressed in the
Same Tumors
While deletion of 13q31–32 has been observed in some
tumors as described above [24–29], paradoxically,
ampliﬁcation at 13q31–32 is also frequently observed in
multiple tumor types, including liposarcoma [43], diffuse
large B-cell lymphomas [44], and colon carcinomas [45]. Fine
mapping of the 13q31–32 region in diffuse large B-cell
lymphomas revealed that C13orf25 is elevated in lymphoma
cell lines and patients [32,46]. Overexpression of miR-17–92
may be particularly tumor-promoting when c-myc is also
activated. Ampliﬁcation of miR-17–92 in the B-cell lymphoma
tumor type is consistent with a role for miR-17–92 in
conjunction with c-myc, because human B-cell lymphomas are
often characterized by high c-myc expression [47]. Elevated
expression levels of miR-17–92 members has also been
associated with lung cell tumors, especially those with c-myc
ampliﬁcation. miR-17–92 overexpression was detected at the
RNA level and in some cases at the DNA level as well,
suggesting ampliﬁcation events [34]. In yet another study, a
human mantle cell lymphoma was shown to contain genomic
ampliﬁcation of both c-myc and miR-17–92 [48].
One simple explanation for the concordance between high
levels of c-myc and miR-17–92 would be that c-myc directly
induces miR-17–92. But this is unlikely to represent the entire
story, as genomic ampliﬁcation of the miR-17–92 cluster has
also been observed [34,48]. In addition, introduction of miR-
17–92 hastens lymphomagenesis in El-myc overexpressing
mice [32]. As described above, lymphomas with high levels of
miR-17–92 exhibited less apoptosis than typically found in c-
myc–overexpressing tumors, consistent with the model that
miR-17–92 overexpression inhibits apoptosis. This ﬁnding
demonstrates that miR-17–92 overexpression confers a
further selective advantage in a high c-myc background.
miR-17–92 as an Integrator of Proliferative versus
Apoptotic Signals?
We conclude by hypothesizing that the unusual structure of
the c-myc–miR-17–92–E2F network may help the cell to
integrate external signals to make a cell fate decision. c-myc
activation can result in proliferation, and indeed, c-myc levels
are often markedly elevated in tumors. However, in different
cellular contexts, c-myc can be a potent inducer of apoptosis
[49–55]. In a mouse model with inducible c-myc, activation of
c-myc in pancreatic b cells induced uniform b cell
proliferation, but also overwhelming apoptosis, thus
counteracting the oncogenic potential of c-myc [56]. When c-
myc was activated in conjunction with overexpression of Bcl-
xL, which suppresses c-myc–induced apoptosis, then c-myc
triggered rapid, uniform, and reversible progression to
tumorigenesis. c-myc/Bcl-xL-induced b cell tumors also
contained an extensive network of blood vessels that
regressed after c-myc was switched off.
We speculate that the miR-17–92 cluster may also have an
important role in the balance between a proliferative versus
apoptotic response to c-myc induction. Under normal
proliferative conditions, induction of miR-17–92 in response
to c-myc activation could serve as a brake on excessive
proliferation. miR-17–92–mediated E2F1 inhibition would
attenuate the hypothetical positive feedback loop of c-myc–
E2F activity. The absence of the miR-17–92–mediated
dampening of proliferative signals could be tumorigenic, and
this might explain the deletions in the 13q31–32 region in
multiple types of tumors [24,25,28]. miR-17–92 induction
would also limit apoptosis under normal proliferative
conditions.
Under other conditions, for instance, in stressful situations,
we hypothesize that c-myc activation might occur in the
absence of miR-17–92 induction. Our model would predict
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less robustly, under conditions in which c-myc activation
results in apoptosis. The molecular mechanisms that control
miR-17–92 in response to c-myc induction are thus of
particular interest. One possible model would be that both c-
myc and E2F are required to induce expression of miR-17–92,
and that the presence of both transcription factors signals to
the cell that c-myc activation should be interpreted as a
proliferative rather than apoptotic signal. In this model, E2F
transcription factors would act as sensors for whether
conditions are suitable for proliferation [14,15]. Monitoring
both miR-17–92 expression and the occupancy of the miR-17–
92 promoter by c-myc and E2Fs in response to proliferative
and apopotic signals would likely shed light on whether the
expression of this cluster reﬂects an ‘‘AND’’ signaling switch.
We further hypothesize that miR-17–92 has a distinct effect
in a c-myc–overexpressing environment. c-myc activation
induces proliferation that is simultaneously held in check by
apoptosis. If a cell has constitutive c-myc overexpression, then
this would override the anti-proliferative effects of the miR-
17–92 cluster. If the same cell also acquires constitutively high
levels of miR-17–92, it will lose the apoptotic response that
keeps its proliferative capacity in check, and may proceed to
proliferate and form a tumor. Thus, overexpression of both c-
myc and miR-17–92 would be expected to create a tumor-
promoting environment. Indeed, overexpression of both c-
myc and miR-17–92 has been observed in the same tumors
[34,48], as described above. Under these conditions, the pro-
angiogenic effects of c-myc and miR-17–92 may also cooperate
with the anti-apoptotic effects of the miR-17–92 cluster to
simultaneously create multiple conditions conducive for a
tumor growth.
Future Research
In summary, a series of elegant recent papers has
illuminated a fascinating and unexpected network of
interactions involving the c-myc and E2F transcription factors,
and the members of a microRNA cluster. This network may
be organized in the format of an incoherent feed forward
loop, in that c-myc induces E2F1 transcription while
repressing E2F1 translation. The microRNAs within this
cluster may act as a brake on proliferation, inhibiting
apoptosis and promoting angiogenesis. We look forward to
further research that will clarify the roles of c-myc, different
E2F transcription factors, and other regulators in controlling
expression of the miR-17–92 cluster. In particular,
experiments addressing whether c-myc and the E2Fs act
synergistically or independently to control miR-17–92
expression would help to deﬁne its potential role as a signal
integrator. It will also be interesting to determine whether
miR-17–92 plays a role in tumorigenesis mediated by other
genetic mechanisms. For instance, in chronic myeloid
leukemias, expression of the miR-17–92 cluster was
downregulated by RNAi directed against the pro-oncogenic
fusion protein bcr-abl [57]. Other microRNAs have been
implicated in tumorigenesis, either as oncogenes or tumor
suppressors [58–60]. The mechanisms by which these
microRNAs affect tumorigenesis, in particular, whether they
affect the same or different molecules and employ the same
or different molecular circuitry, would shed light on the key
elements in the transition to tumorigenesis. Recent analysis
of gene expression patterns between microRNAs and their
targets suggest that networks of this type, in which the
expression of the microRNA and its targets are positively
correlated, are common in human and mouse, especially in
neural tissues [23]. This makes it of particular importance to
discover the potential advantages conferred by this seemingly
paradoxical network structure. “
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